Inclusion Criteria:
* Age: Adults ≥ 18 years.
* Diagnosis: Clinical diagnosis of mild to moderate dry eye disease in at least one eye with OSDI ≥ 13 to ≤ 32 at screening.
* OSDI ≥ 13 to ≤ 32 at screening.
* Objective evidence: NITBUT ≤ 10 seconds in the study eye(s) at screening.
* Ocular surface status: CFS ≤ grade 3 (Oxford or NEI scale) in the study eye(s).
* Stable medications: Systemic medications that may affect tear film must be stable ≥ 30 days prior to screening and expected to remain stable during the study.
* Ability to participate: Able and willing to comply with procedures, attend visits, and provide written informed consent.
* Contraception: Women of childbearing potential must agree to use an acceptable method of contraception for the study duration and have a negative pregnancy test at screening.
Exclusion Criteria:
* Active ocular infection or inflammation unrelated to DED (e.g., bacterial/viral conjunctivitis, active uveitis).
* Severe ocular surface disease beyond typical DED (e.g., severe keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid).
* Excessive corneal staining: CFS \> grade 3 in the study eye(s).
* Recent ocular surgery or procedure: ocular surgery, laser, or punctal occlusion within 6 months prior to screening.
* Current or prior use within 6 months before screening of either study drop (Systane PRO PF or Blink Triple Care PF)
* Contact lens wear: soft or rigid contact lens use within 7 days prior to baseline, or unwillingness to discontinue lenses for the study; consider extending to 14 days if desired.
* Use of topical ophthalmic medications that cannot be discontinued (e.g., topical antibiotics, corticosteroids).
* Recent investigational product use: participation in another interventional trial or investigational product use within 30 days prior to screening.
* Known hypersensitivity: allergy to any component of Systane PRO PF or Blink Triple Care PF.
* Confounding systemic conditions: systemic diseases or medications that, in the investigator's judgment, could significantly affect tear production or ocular surface health (e.g., uncontrolled autoimmune disease, recent initiation/change of systemic medications known to affect tear production within 30 days).
* Severe visual impairment in the study eye(s) not attributable to DED that would interfere with assessments.
* Pregnancy or breastfeeding.
* Investigator discretion: any medical, psychiatric, or social condition that would preclude safe participation or reliable completion of study procedures.
